Coronary Artery Disease and Stable Angina

Coronary artery disease (CAD) management addresses the long-term care of patients with atherosclerotic narrowing of the coronary arteries, which can produce stable angina — predictable, exertional chest discomfort from myocardial ischaemia. Once an acute event is excluded, management is a chronic, secondary-prevention task centred on reducing future cardiovascular events and controlling symptoms.

Definition

Coronary artery disease and stable angina management is the longitudinal secondary prevention and symptom control of patients with chronic atherosclerotic coronary disease, combining risk-factor modification, antianginal and preventive therapies, and — in selected cases — revascularisation, within continuous care.

Scope

This entry describes the conceptual basis of managing stable coronary artery disease (chronic coronary syndrome) in long-term care: the mechanism of demand-ischaemia, the goals of symptom relief and event prevention, and the landmark trials and guidelines comparing medical therapy with revascularisation. It is a reference orientation and does not provide individualised treatment, drug, or procedural guidance.

Core questions

• How does coronary atherosclerosis produce stable, exertional angina?
• What are the goals of managing chronic coronary disease once an acute event is excluded?
• When does revascularisation add benefit over optimal medical therapy for stable disease?
• How is secondary prevention integrated with management of diabetes, hypertension, and lipids?

Key concepts

• Coronary atherosclerosis
• Myocardial ischaemia and supply-demand mismatch
• Stable angina pectoris
• Chronic coronary syndrome
• Optimal medical therapy
• Revascularisation (PCI and CABG)
• Secondary prevention and risk-factor modification

Mechanisms

Atherosclerotic plaque narrows the coronary arteries, limiting the increase in blood flow needed during exertion; when demand outstrips supply, transient myocardial ischaemia produces angina. Chronic management targets the underlying atherosclerotic process through risk-factor control and preventive therapy, while antianginal treatment addresses the supply-demand mismatch. Revascularisation can relieve flow-limiting lesions but, in stable disease, its effect on hard outcomes is more limited than its effect on symptoms.

Clinical relevance

Stable coronary artery disease is a common chronic condition encountered and co-managed in primary care, and its long-term secondary prevention substantially influences cardiovascular outcomes, making it a core chronic-disease topic. This entry explains how that management is conceived and supported by evidence; it is not a basis for individual diagnosis, drug selection, or decisions about procedures.

Epidemiology

Coronary artery disease is a leading cause of death and disability worldwide and a major component of the global cardiovascular burden. It shares modifiable risk factors — smoking, hypertension, dyslipidaemia, diabetes, and physical inactivity — with the other conditions managed in chronic-disease care, with which it frequently co-occurs.

Evidence & guidelines

The COURAGE trial (Boden and colleagues, 2007) and later the ISCHEMIA trial (Maron and colleagues, 2020) showed that, for many patients with stable coronary disease, an initial strategy of optimal medical therapy yields outcomes comparable to routine early revascularisation for preventing major events, while revascularisation can improve symptoms. The 2019 ESC guidelines on chronic coronary syndromes (Knuuti and colleagues) integrate this evidence into a framework emphasising risk assessment, prevention, and individualised use of revascularisation.

History

Stable angina was long understood mechanically as a flow-limiting problem, encouraging an expectation that opening narrowed arteries would improve outcomes. Randomised trials from 2007 onward — COURAGE and then ISCHEMIA — challenged routine early revascularisation for stable disease by showing comparable event rates with optimal medical therapy, reframing chronic coronary disease as primarily a medical, secondary-prevention condition and prompting the reconceptualisation of stable CAD as a 'chronic coronary syndrome'.

Debates

Revascularisation versus optimal medical therapy for stable coronary disease

Trials show that, for many patients with stable disease, initial medical therapy prevents major events as effectively as early revascularisation, which mainly improves symptoms; the appropriate role and timing of revascularisation in stable disease remains actively debated.

Key figures

• William E. Boden
• David J. Maron
• Judith S. Hochman
• Juhani Knuuti

Seminal works

• boden-2007
• maron-2020
• knuuti-2019

Frequently asked questions

What is the difference between stable angina and a heart attack?

Stable angina is predictable, exertional chest discomfort from reversible myocardial ischaemia that resolves with rest, whereas a heart attack (acute coronary syndrome) involves sustained ischaemia from an acutely disrupted artery and is a medical emergency; this entry concerns the chronic, stable condition.

Does opening a narrowed coronary artery always improve outcomes in stable disease?

Not necessarily. Trials such as COURAGE and ISCHEMIA found that, for many patients with stable coronary disease, optimal medical therapy prevents major events as well as early revascularisation, which mainly helps with symptoms; decisions are individualised.